EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients

Narmin Naghizade, Tuğba Tolu, Yeşim Özen Alahdab, Özlen Atuğ, Haluk Tarık Kani

Journal of Enterocolitis · 2026

DOI: 10.14744/jenterocolitis.2026.80717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enterocolitis, 2026. Verfasst von Narmin Naghizade und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Naghizade, N., Tolu, T., Alahdab, Y. Ö., Atuğ, Ö., & Kani, H. T. (2026). Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients. Journal of Enterocolitis. https://doi.org/10.14744/jenterocolitis.2026.80717

Vancouver

Naghizade N, Tolu T, Alahdab YÖ, Atuğ Ö, Kani HT. Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients. Journal of Enterocolitis. 2026. doi:10.14744/jenterocolitis.2026.80717

BibTeX
@article{Naghizade2026,
  author = {Naghizade, Narmin and Tolu, Tuğba and Alahdab, Yeşim Özen and Atuğ, Özlen and Kani, Haluk Tarık},
  title = {Efficacy and Safety of Vedolizumab and Ustekinumab Treatment in Anti-TNF-Exposed Inflammatory Bowel Disease Patients},
  journal = {Journal of Enterocolitis},
  year = {2026},
  doi = {10.14744/jenterocolitis.2026.80717}
}
Kostenlos starten →